BNA is an FDA-cleared technology that objectively measures and maps the neuronal network activity responsible for brain function. It has the potential to impact an estimated two billion people worldwide living with neurological and psychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, depression, and ADHD, as well as those who have sustained brain injuries. BNA is not limited for a specific ailment but rather is a test that provides clinicians with quantitative and qualitative information on the brain’s functional networks.
Briana was introduced to BNA™ (Brain Network Activation) earlier this year and discovered that the state-of-the-art technology is a game-changer for people like herself who have been susceptible to and impacted by brain injuries in the sports field. Briana aims to educate the public on the capabilities of ElMindA’s technology – so that those already affected by brain injury may receive more targeted treatment and that those engaging in activities that put them at-risk may better manage and minimize the effects of potential injuries.
Learn more about BNA at www.mybna.com